BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, May 15, 2026
Home » Blogs » BioWorld MedTech Perspectives » Could crowdfunding be the savior of early-stage med-tech?

BioWorld MedTech Perspectives
BioWorld MedTech Perspectives RSS FeedRSS

Medical technology

Could crowdfunding be the savior of early-stage med-tech?

Oct. 25, 2013
By Omar Ford

crowd-fundingIt's no secret that it's harder and harder for med-tech firms to receive early stage funding. I think my last six blogs have been about that topic alone.

But while its true that some venture capital firms are looking to invest in med-tech companies at a later stage in the development cycle, some firms are getting fairly creative and are going toward crowdfunding.

Last  week, I wrote a story about Amulyte (Markham, Ontario), a company that has developed an emergency response device that helps seniors live on their own terms, and its move toward the crowdfunding model. The company partnered with WeFunder, a recently launched Crowd Investing platform that helps early stage companies secure investment.

It was an interesting interview and Mike Norman co-founder and president of WeFunder spoke on some ambivalence that some companies might have toward going this route.

“Any time there’s a new innovation out there with something as critical as fundraising . . . people really want to understand how it works,” he said in an interview with Medical Device Daily. “We have had to make our model look as similar to existing fundraising as possible. One of the things that start-ups get concerned about is having hundreds of investors in the company with voting rights and they have to get signatures from these investors, which are just hard to track down in general, when they want to make large company decisions. What we do is we take all the investors that come in through the WeFunder and they invest in a single LLC that then invests in the company.”

He then said that because of this measure there is only one shareholder on the company’s cap table.

With this kind of model in place I have to wonder if med-tech firms truly want to keep up with the times and foster innovation, could they quite possibly think about crowdfunding as a means of early-stage funding?

We're in an era where med-tech companies that think outside the box could lead the pack in innovation. Could crowdfunding be the next logical step in achieving this goal?

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 15, 2026.
  • Illustration of a glowing circle to represent circRNA

    ASGCT 2026: Circular RNA, the new beast in gene and cell therapy

    BioWorld
    Circular RNA (circRNA) is not a new concept, but it is a novel strategy in the field of gene and cell therapy. While mRNA vaccines have revolutionized medicine,...
  • Brain maze

    Alzheimer’s, beyond the brain

    BioWorld
    Researchers at Daping Hospital in China have reported that liver-targeted delivery of the APOE3-Christchurch (APOE3Ch) variant, a rare protective form of...
  • Test tubes, dropper and capsules

    Advancing the 'best of both' – BMS, Hengrui enter $15.2B deal

    BioWorld
    In a deal potentially worth up to $15.2 billion, Jiangsu Hengrui Pharmaceuticals Co. Ltd. is joining efforts with Bristol Myers Squibb Co. to advance 13 early...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for May 12, 2026
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing